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Abstract
The thyroglobulin type-1 (Tg-1) domain is a protein mod-
ule that occurs in a variety of secreted and membrane
proteins and is recognised as a potent inhibitor of cys-
teine peptidases. We present here some properties of the
Tg-1 domain of human testican, a modularly organised
proteoglycan secreted mainly by brain cells, the exact in
vivo function of which is not yet clear. The domain was
prepared as a recombinant protein in a Pichia pastoris
expression system and its activity was demonstrated by
specific and selective inhibition of cathepsin L
(Kis0.14 nM). Interaction at high enzyme and inhibitor
concentrations resulted in degradation of the domain by
cathepsin L, which was not observed under conditions
used for the determination of kinetic parameters. No
inhibitory activity could be detected for cathepsin K, but
it exhibited a very similar degradation pattern. Homology
modelling provided a good explanation for the different
behaviour observed with the two enzymes. Firstly, the
steric fit between the interfaces of testican domain and
cathepsin L is stabilised by numerous favourable forces,
while no such interactions are evident in the complex
with cathepsin K, and repulsive interactions even prevent
access of the domain to the active site of papain. Sec-
ondly, the prolonged first loop of the domain occupies a
position near the catalytic cysteine residue in a more
substrate-like manner, enabling cleavage of the Gly22-
Ala23 bond.
Keywords: cysteine peptidases; extracellular
proteolysis; inhibition kinetics; proteoglycans; testican;
thyropin.
Introduction
Thyroglobulin type-1 (Tg-1) domains are recognised as
unique sequence motifs of 65–80 residues. They occur
in a variety of modularly organised proteins that are either
secreted or located in membranes (Molina et al., 1996;
Lenarcˇicˇ and Bevec, 1998). A few years ago, it was
established that some proteins containing a Tg-1 module
function as inhibitors of the papain-related cysteine pep-
tidases. So far, five proteins have been characterised as
true inhibitors, the p41 invariant chain fragment (Bevec
et al., 1996), chum salmon egg cysteine peptidase inhib-
itor (Yamashita and Konagaya, 1996), equistatin (Lenarcˇicˇ
et al., 1997), saxiphilin (Lenarcˇicˇ et al., 2000) and testican
(Bocock et al., 2003). All these inhibitors differ signifi-
cantly in their selectivity for target enzymes. For example,
the p41 fragment can discriminate between two closely
related enzymes, cathepsin L and cathepsin S, inhibiting
only the former (Bevec et al., 1996). Only one of the two
Tg-1 domains present in saxiphilin inhibits cathepsins L
or B (Lenarcˇicˇ et al., 2000) and, in the case of the three
equistatin domains, the first one exhibits broad specific-
ity against papain-like cysteine peptidases, while the
subsequent two are non-inhibitory (Lenarcˇicˇ and Turk,
1999; Galesˇa et al., 2003). Furthermore, the second Tg-
1 domain of equistatin is unique in inhibiting the aspartic
peptidase cathepsin D (Galesˇa et al., 2003). The general
inhibitory mechanism of a Tg-1 domain was revealed by
the crystal structure of the p41 fragment in complex with
cathepsin L (Guncˇar et al., 1999). The wedge shape and
the three-loop arrangement of the p41 fragment interacts
with the active site cleft in a non-specific manner, where-
as the additional contacts between regions of the inhib-
itor with the right domain of the enzyme are supposed to
be crucial for the specificity. The structure of the p41
fragment is stabilised by three disulfide bridges and is
also well defined in the absence of enzyme (Chiva et al.,
2003).
Testican is a proteoglycan expressed predominantly in
brain (Bonnet et al., 1996). At the genetic level, two addi-
tional forms of testican have been identified, testican-2
(Nagase et al., 1996; Vannahme et al., 1999) and testi-
can-3 (Nakada et al., 2001). The characteristic feature of
all variants is their modular organisation. The signal
sequence on the N-terminal end is followed by a short
part unique to testican, the follistatin domain, which also
includes a Kazal domain, the calcium-binding domain, by
the thyroglobulin type-1 domain (Tg-1), and finally by a
short C-terminal sequence where two glycosaminogly-
can attachment sites are located. The latter modification
is suggestive of its involvement in cell adhesion process-
es and extracellular matrix organisation (Hartmann and
Maurer, 2001). Lysosomal peptidases are known to be
secreted into the peri/extracellular space, where they
take part in remodelling or pathological degradation of
extracellular matrix proteins in processes such as osteo-
arthritis, angiogenesis and inflammatory response (Baici
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Figure 1 CD spectra of the testican Tg-1 domain under normal
and denaturing conditions.
CD spectra were recorded using a protein concentration of
0.1 mg/ml in 10 mM sodium phosphate buffer, pH 5.60. (d) Tes-
tican Tg-1 domain measured at 48C; and (s) testican Tg-1
domain in the presence of 12.5 mM DTT, measured at 888C.
et al., 1995; Chapman et al., 1997; McGrath, 1999).
Recently, a model of the involvement of the p41 invariant
chain Tg-1 domain in the regulation of extracellular
cathepsin L activity was presented (Fiebiger et al., 2002).
It was shown that a stable complex of cathepsin L/p41
fragment is formed within antigen presenting cells and is
afterwards secreted into the extracellular milieu, where
the Tg-1 domain of p41 most probably acts to protect
the enzyme and is displaced by a physiological substrate
when necessary.
In the present study we characterised the Tg-1
domain, a 7-kDa fragment of the 49-kDa full-length
human testican, which shows significant sequence sim-
ilarity to the Tg-1 domains of the p41 invariant chain and
equistatin, for which the specificities against different
peptidases have already been determined in detail
(Bevec et al., 1996; Lenarcˇicˇ and Turk, 1999; Lenarcˇicˇ et
al., 2000). Using the expression system of Pichia pasto-
ris, we produced the Tg-1 domain in an apparently native
form. Molecular modelling and functional analyses
revealed new features about the interaction of testican
Tg-1 domain with its target papain-like enzymes.
Results and discussion
Preparation of recombinant Tg-1 domain of testican
P. pastoris proved to be a highly effective heterologous
system for generating functional Tg-1 domains of equi-
statin in high yield (Galesˇa et al., 2003). In the present
study, we utilised the same system to produce the Tg-1
domain of human testican. The cDNA construct for Tg-1
domain coding for 70 amino acids (Gly310–Glu379, testican
unprocessed precursor counting) was introduced into the
P. pastoris GS115 strain and the level of the expressed
protein in media was followed by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE)
(data not shown). The domain was purified by three chro-
matographic steps and at the end a single band on
SDS-PAGE corresponding to a molecular mass of
approximately 8 kDa was obtained (data not shown). In
the final purity assessment by N-terminal sequencing, we
detected three slightly different populations of domains.
In approximately 60% of the molecules two Glu-Ala
repeats (out of three) were missing at the N-terminus, in
25% of the molecules one Glu-Ala repeat had been
removed, and 15% of the molecules had the sequence
of the intact Tg-1 domain. Processing of a-MF propep-
tide from the recombinant protein by the Kex2 endopep-
tidase appeared to be efficient, while the efficiency of
Ste13 in removing the Glu-Ala repeats was not absolute.
Similarly, it was observed that the two Glu-Ala repeats
begin the sequences of previously reported Tg-1
domains of equistatin expressed in P. pastoris (Galesˇa et
al., 2003), confirming the fact that the precise action of
Ste13 depends on the surrounding amino acid sequence
and on the tertiary structure of the protein of interest
(Brake et al., 1984; Cereghino and Cregg, 2000). A yield
of 10 mg of pure, active testican Tg-1 domain was typ-
ically obtained from 1 l of culture medium.
CD spectrum of testican Tg-1 domain
The CD spectrum of the Tg-1 domain of testican is cha-
racterised by two peaks, a positive one at 230 nm and
an intense double trough at 204 nm (Figure 1). The spec-
trum differs slightly from the spectra of the individual Tg-
1 domains of equistatin (Galesˇa et al., 2003) in two
respects, by having a pronounced double trough and by
the fact that both peaks are shifted to slightly higher
wavelengths. As a comparison, the first domain of equis-
tatin has negative peaks at 200, 194 and 198 nm, while
the positive peak, which reflects the aromatic contribu-
tion (Woody, 1994) is present only in the second domain
at 220 nm. A similar strongly positive band at 226 nm
has also been observed with synthetic p41icf Tg-1
domain (Chiva et al., 2003). The small differences
observed in the CD spectra are probably a consequence
of slightly different backbone conformations of individual
domains, which might in turn correspond to different
specificities. On the other hand, it appears that the gen-
eral features of all known Tg-1 domain spectra are char-
acteristic of the thyropin fold. It very much resembles
spectra of a group of b-proteins in which the a-helix con-
tent is low (Koepf et al., 1999; Kidricˇ et al., 2002). When
the testican domain was thermally unfolded, the spec-
trum exhibited the characteristics of a random coil (Fig-
ure 1).
Inhibition of cathepsin L by the Tg-1 domain of
testican
An important characteristic of thyroglobulin type-1
domains is their selectivity in inhibiting different papain-
like enzymes (Bevec et al., 1996; Lenarcˇicˇ et al., 1997,
2000). To investigate the inhibitory capacity of the testi-
can Tg-1 domain we considered the human lysosomal
cysteine peptidases cathepsins B, K, L, S, and X, and
the plant cysteine peptidase papain, as well as the aspar-
tic peptidase cathepsin D and the serine peptidase tryp-
sin. Only cathepsin L was inhibited, while all of the other
enzymes were not affected, even at high inhibitor con-
centrations. Cathepsin K rapidly cleaved the Tg-1
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Scheme 1 Reaction mechanism proposed for cleavage of the
Tg-1 domain by cathepsin L.
domain (see next section), while cathepsins B, S, X, and
D, as well as papain and trypsin, did not. For cathepsin
L, Eq. (1) was used to calculate ys, yz and l (see Mate-
rials and methods). ys was a hyperbolic function of wTg-
1x and dropped to zero at saturating inhibitor
concentrations, yz was independent of wTg-1x, and l
depended linearly upon wTg-1x over the whole concen-
tration range explored. The inhibitor affected Km, but not
the limiting rate V. This behaviour is characteristic of a
fully competitive, slow-binding inhibition mechanism, in
which the enzyme-inhibitor complex is formed in a single
step (Morrison, 1982). Cleavage of the Tg-1 domain by
cathepsin L was observed under second-order reaction
conditions at high enzyme and Tg-1 concentrations (next
section). The proposed complete reaction mechanism,
including the substrate used to monitor reaction, is
shown in Scheme 1.
I* collectively represents all possible fragments gen-
erated by proteolysis. Following the first attack on the
most susceptible bond, two new peptides are generated
and then smaller peptides are formed from these. If these
are substrates for the enzyme, the system will consist of
a mixture of substrates with different affinities. Thus, the
path leading to I* contains multiple steps that remain
kinetically inaccessible to experimental verification and
is represented by the global constant k*. Best-fit par-
ameters and their standard errors, calculated by non-
linear regression, were: k3s(8.94"0.35)=106 M-1 s-1;
k-3s(1.28"0.23)=10-3 s-1; and Kisk-3/k3s(1.4"0.3)=10-
10 M. There was no evidence that the Tg-1 domain was
cleaved by proteolysis, thus behaving as a substrate,
during assays with catalytic enzyme concentrations. In
this case the steady-state slope had turned to a con-
cave-upward profile for long reaction times. For calcu-
lation we used the concentration of the Tg-1 domain as
determined spectrophotometrically. A titrated concentra-
tion of the Tg-1 domain was not available, since the only
enzyme with which this would be possible is cathepsin
L. Titration inevitably involves the use of both enzyme
and inhibitor at relatively high concentrations, and under
these conditions the inhibitor is degraded (see below).
The high quality of the CD spectrum (Figure 1), which
shows a remarkable difference between the native and
the unfolded polypeptide, suggests that our testican Tg-
1 domain preparation was properly folded and active.
The inhibitory behaviour of the isolated Tg-1 domain
towards cathepsin L is thus very similar to that of intact
testican, with Ki values of 0.14 nM (this study) and 0.7 nM
(Bocock et al., 2003). These results are in good agree-
ment with our previous studies on equistatin
(Lenarcˇicˇ et al., 1997; Galesˇa et al., 2003) and the p41
fragment invariant chain (Bevec et al., 1996; Fiebiger et
al., 2002), in which we demonstrated that the Tg-1
domains fully retain their functionality after excision from
the rest of the parent molecule. Therefore, the testican
Tg-1 domain may serve as a good model for further cha-
racterisation of the action of this type of inhibitor.
Degradation of Tg-1 domain of testican by
cathepsins L and K
The kinetic measurements for inhibition of cathepsin L by
testican Tg-1 domain were carried out with Tg-1 domain/
cathepsin L molar ratios in the range 130:1–550:1 and
picomolar enzyme concentrations. When molar ratios of
1:1–6:1 and concentrations of enzyme and inhibitor in
the micromolar range were used, extensive degradation
of the inhibitor molecule was observed. Reaction pro-
gress was followed by HPLC separation of the frag-
ments, and degradation products were analysed by
matrix-assisted laser desorption/ionisation time-of-flight
mass spectrometry (MALDI-TOF). A large number of frag-
ments observed (Tables 1 and 2) were due to the pres-
ence of three differently expressed forms of testican Tg-1
domains and to partial reduction of the disulfide bridges
during the process of cleavage. For the purposes of anal-
ysis we have omitted fragments that evidently arise from
the minor E-4 and Gly1 forms. The time-dependent deg-
radation of the domain enabled us to reveal the sequence
of cleavage events. Within the tight cathepsin L/Tg-1 tes-
tican domain complex, the most susceptible bond
appeared to be Gly22–Ala23. These amino acids are locat-
ed at the bottom of the first loop in the close vicinity of
the cathepsin L active site. After this primary cleavage,
the first loop was attacked at two further sites: (i)
between Gln12-Lys13 and/or Asn9-Arg10, resulting in the
excision of corresponding short peptides that occupy the
active site (Lys13-Gly22 and Arg10-Gly22, respectively); (ii)
the bonds between Tyr34-Lys35 and Lys35-Ala36 became
exposed at the same time, and their cleavage provoked
the complete separation of the first loop from the rest of
the molecule. Prolongation of the incubation time
brought about only the release of disulfide-bonded frag-
ments (Table 1).
The interaction of cathepsin K with the testican domain
resulted in its rapid cleavage (Table 2). No inhibition of
the enzyme could be detected, although it cannot be
excluded that, during the interaction, the domain may
enter the active site of cathepsin K as thyropin-like inhib-
itors normally do, i.e., with all three loops (Guncˇar et al.,
1999). The most exposed region of the Tg-1domain to
cathepsin K was again the extended first loop, where the
main fragmentation took place (Ser15-Lys16, Leu21-Gly22
and Gly22-Ala23). Prolongation of the incubation time
resulted in additional cleavages between Gln12-Lys13 and
on the C-terminal part of the Tg-1 molecule (Ala57-Gly58
and Ala64-Val65).
Cysteine peptidases of the papain family have been
shown to have primary substrate specificity at the P2
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position and to have a preference for hydrophobic amino
acids (McGrath, 1999; Turk et al., 1998). Despite struc-
tural similarities, cathepsins L and K display differences
in their binding preferences for P2 residues. Cathepsin L
favours both aromatic and aliphatic amino acid residues
(Phe, Tyr, Trp, Val, Leu, Ile), while cathepsin K favours
aliphatic amino acids (Ile, Leu, Val) and is unique in posi-
tioning Pro in the S2 subsite, a property responsible for
its potent intrahelical collagenolytic activity (Garnero et
al., 1998; Lecaille et al., 2002). Our present results show
that the amino acid residues at P2 subsites of the iden-
tified cleavage points of the testican Tg-1 domain reflect
the specificity of the cathepsin considered (Tables 1 and
2). Cathepsin L shows broader selection of amino acids
at the P2 position by utilising Tyr, Leu, Ile and Val, and
can also employ Met and Ala, while cathepsin K is limited
to Leu and Ile, with the one exception for Gly.
Evidence from experiments conducted under different
conditions suggests that the dual nature of the Tg-1 tes-
tican domain as substrate and inhibitor of cathepsin L is
due to the very low rate of degradation of the EI complex
according to Scheme 1. An estimate for the rate of deg-
radation of the Tg-1 domain was obtained from the time-
dependent degradation of the inhibitor after incubating
0.39 mM cathepsin L with 2.3 mM Tg-1 domain at 248C
and pH 5.50 (data not shown). The final degradation
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products of the Tg-1 domain were no longer inhibitory,
as ascertained by incubating them with cathepsin L and
measuring the residual activity with Z-Phe-Arg-MCA
(MCA, 4-methyl-7-coumarylamide) as substrate. Since
evaluation of all the individual constants contributing to
k* in Scheme 1 was impossible, quantification was car-
ried out by measuring the decreasing area of the HPLC
peak corresponding to the Tg-1 domain and reaction
profiles were analysed by the integrated Michaelis-Men-
ten equation. Calculations afforded a first-order rate con-
stant of 1.33=10-4 s-1 (half-lifes5200 s), equivalent to
V/Km for the most susceptible bond of the Tg-1 domain,
i.e., the first one cleaved by cathepsin L. Considering this
result and the enzyme concentration used (0.39 mM), a
first-order rate constant of 7.5=10-9 s-1 (half-
lifes9.2=107 s) can be calculated for an enzyme con-
centration of 22 pM, i.e., the concentration used for
measuring the inhibition constant (see the preceding
section). Hence, the rate of Tg-1 domain degradation at
catalytic enzyme concentration is approximately 18 000-
fold lower than at high enzyme concentrations. Degra-
dation is virtually invisible, and the Tg-1 domain behaves
as an inhibitor. Cathepsin L used for the experiments
shown in this paper was prepared in E. coli from inclusion
bodies and was obtained by renaturation, thus making
the presence of contaminating bacterial peptidases very
unlikely. In order to rule out the possibility that Tg-1
domain degradation was not due to cathepsin L but to a
contaminant enzyme, we repeated the cleavage experi-
ment and fragment analysis using the same Tg-1 domain
preparation and cathepsin L from two additional sources,
namely the natural enzyme purified from human kidney
and a recombinant form from Pichia pastoris. With all of
the three different enzyme preparations we obtained the
same cleavage products (data not shown).
Structural analysis of models
To explain the experimentally observed specific interac-
tion of the Tg-1 domain of testican with cathepsin L, sev-
eral models of their complex were built and compared to
the models of complexes of the domain with cathepsin
K and papain. The models were derived by a homology
modelling procedure with amino acid sequence identity
between the Tg-1 domain of testican and the template
structure (p41 fragment) being above 30%. The major
differences between the two molecules are present in the
first subdomain and are a consequence of the insertion
of five amino acids in the testican Tg-1 domain com-
pared to the p41 fragment (Figure 2A). In the modelled
domain, the extended a-helical region contributes to
hydrophobic packing, and the region following the a-
helix forms an enlarged loop that may have a more flex-
ible conformation, similar to the corresponding loop in
the p41 fragment, as observed from its NMR structure
(Chiva et al., 2003). The interactions between the testican
Tg-1 domain and cathepsin L in the modelled complex
are electrostatic, polar and hydrophobic. Lys18 interacts
electrostatically with Asp71E and Asp114E, and Arg27 and
Lys35 with Asp137E, Asp160E and Asp162E, the latter three
forming the S19 binding site (the letter E denotes enzyme
residues). Polar interactions occur between Ser42 and
both Cys25E and Gln21E, the latter representing the oxy-
anion hole. Hydrophobic interactions predominantly
involve Leu21, which fits into the deep and hydrophobic
S2 binding pocket of cathepsin L, and are mainly con-
fined to the first and second loops of the domain (Figure
2B). These interactions are similar to interactions
observed in the crystal structure of the p41 fragment
complex with cathepsin L. Models of complexes of the
domain with cathepsin K and papain (Figure 2C,D,
respectively) show the same general binding mode,
although the majority of favourable electrostatic interac-
tions observed in the cathepsin L complex are not pres-
ent. These observations are consistent with the finding
that neither cathepsin K nor papain was inhibited by the
Tg-1 domain. Furthermore, the surface of papain near the
domain in the modelled complexes is positively charged,
which may prevent binding of the domain to the enzyme
(Figure 2D). These results lead to the conclusion that the
domain binds to both cathepsin L and K, but not to
papain.
It is still not possible to establish whether proteolytic
cleavage of the domain by cathepsins L and K is a con-
sequence of the geometry of the prolonged first loop or
of the amino acid composition at the P4-P1/P19 site, or
maybe a combination of both. For example, testican and
the first domain of equistatin exhibit a very similar
arrangement of amino acid residues at P4-P1/P19 posi-
tions within the first loop, i.e., Ser-Leu-Leu-Gly/Ala and
Gly-Leu-Ile-Gly/Ala, respectively (Lenarcˇicˇ et al., 1997).
Only testican is cleaved by cathepsin L, which points to
the position of the extended loop as a decisive factor.
This could be explained by the more substrate-like nature
of the extended first loop of the testican Tg-1 domain
compared to the corresponding loop of the first domain
of equistatin, which presumably is tighter and similar to
the corresponding loop in the p41 fragment. However,
another prerequisite for proteolytic cleavage is the acces-
sibility of the scissile bond for nucleophilic attack of the
sulfur atom of the active Cys residue (Figure 2E,F). This
accessibility is in turn governed by the residues sur-
rounding the putative cleavage site and their conforma-
tion. Finally, it should be noted that the interacting region
of the testican Tg-1 domain is clearly different from a
classical substrate, since it is not linear but rather com-
posed of two parts, one of them interacting with S bind-
ing subsites and the other with S9 binding subsites.
Nevertheless, the modelling results suggest that binding
of the domain to the enzyme in an orientation similar to
that found in the cathepsin L-p41 fragment complex is a
prerequisite for proteolytic cleavage of the domain, since
this is the only orientation that permits close contact
between the domain and the enzyme.
Physiological aspects
There are several reports about the proteolytic process-
ing of molecules that contain Tg-1 domains. Two C-ter-
minal testican fragments (cleavage within the Tg-1
domain at position Tyr343-Lys344 and Arg369-Lys370) with
attached chondroitin sulfate chains were found as the
major proteoglycans in human seminal plasma (Bonnet
et al., 1992). The Tyr343-Lys344 bond (testican unproces-
sed precursor counting) corresponds to the Tyr34-Lys35
bond (Table 1), which is one of the cleavage points
80 P. Meh et al.
Article in press - uncorrected proof
Figure 2 Three-dimensional models of testican Tg-domain in complex with target enzymes.
(A) Superimposition of the testican Tg-1 domain model (grey) and the p41 fragment (black). The insertion of five amino acids in the
testican domain, as compared to the p41 fragment, results in an extended a-helix and altered geometry of the first loop. (B–D)
Models of complexes of testican Tg d-1 domain and cathepsin L (B), cathepsin K (C) and papain (D). The surface of enzymes is
shaded to represent the electrostatic potential: negatively charged residues are shown in grey and positively charged residues in
black. Positively charged amino acid residues of the testican domain involved in favourable (cathepsins L and K) or unfavourable
(papain) electrostatic interactions are shown as black sticks. (E,F) Testican Tg-domain displayed over the surfaces of the active sites
of cathepsins L (E) and K (F). The position of the scissile bond (marked with an arrow) in the testican Tg d-1 domain relative to the
active site cysteine residue (Cys25E) is similar for both cathepsin L and K. In this substrate-like orientation, the P2 residue (Leu21) fits
into the hydrophobic S2 binding pocket of the enzyme. Images were generated using the program MOLMOL (Koradi et al., 1996).
detected after the interaction of the domain with cathep-
sin L. Interestingly, the Tg-1 domain was also proposed
as a target cleavage region during the conversion of large
plasma testican into smaller stable forms, although it was
shown that processing can be blocked by certain serine
peptidase inhibitors (BaSalamah et al., 2001). Neverthe-
less, in the present work we demonstrated that the Tg-1
domain of testican is very susceptible to cleavage by the
two cysteine peptidases cathepsin L and cathepsin K.
Therefore, the role of the testican Tg-1 domain must be
different from that of the Tg-1 domain of the major his-
tocompatibility complex class II associated invariant
chain (p41 Ii), the processing of which has been studied
in more detail (Fiebiger et al., 2002). Two key enzymes
are crucial for processing p41 Ii, cathepsins S and L (Len-
non-Dumenil et al., 2002) and, from the point of view of
the Tg-1 domain, it remains intact after proteolysis and
can serve either as an inhibitor of cathepsin L activity or
as a chaperone in maintaining the pool of mature enzyme
outside the cell (Fiebiger et al., 2002). The major differ-
ence between the two domains is the insertion of five
amino acids on the N-terminal part of the testican
domain, which probably has a great impact on the geom-
etry and position of the first loop and consequently on
the susceptibility to proteolytic attack.
In the light of the results reported here, testican may
behave as an inhibitor or as a substrate of cathepsin L,
depending on the relative concentrations available. In a
close pericellular environment, where cathepsin L is likely
to reach considerable local concentrations, proteolytic
fragmentation of testican can be expected. Conversely,
at a certain distance from a cathepsin L-releasing cell,
the enzyme concentration is likely to be sufficiently low
with respect to the proteoglycan to make proteolysis
insignificant relative to inhibition. Further studies will be
needed to focus on the possible physiological role of Tg-
1 domains in the peri/extracellular space, where several
cysteine peptidases are known to play an important role
in remodelling of extracellular matrix proteins (McGrath,
1999). A number of modularly organised proteins with
diverse functions, such as testican, nidogen, thyroglo-
bulin, Trop and SMOC that contain one or more copies
of Tg-1 domains, are considered to be extracellular
proteins.
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Materials and methods
Materials
Materials for cloning, expression and purification were obtained
from the following sources: polymerase chain reaction (PCR)
primers from MWG Biotech (Ebersberg, Germany); restriction
enzymes, DNA ligase and deoxynucleotide from Promega (Mad-
ison, USA); Taq polymerase from Fermentas (Vilnius, Lithuania);
salts and media for P. pastoris from Sigma-Aldrich (St. Louis,
MO, USA); P. pastoris expression kit, pPIC9 plasmid and P. pas-
toris strain GS115 from Invitrogen (Carlsbad, CA, USA); Phenyl
Sepharose, Sephadex G-50 and SP Sepharose FF from Amer-
sham Pharmacia Biotech (Uppsala, Sweden); and Z-Phe-Arg-4-
AMC, Z-Phe-Val-Arg-AMC, Z-Arg-Arg-AMC and Z-Phe-Arg-pNA
from Bachem AG (Bubendorf, Switzerland). 2,4-Dinitrophenyl-
Gly-Phe-Phe-Trp-OH was synthesised according to Klemencˇicˇ
et al (2000) and the cDNA coding for the testican protein was
kindly provided by C.J.S. Edgell (University of North Carolina,
USA). Papain was prepared as described in Blumberg et al.
(1970), human cathepsins B, D, L, K, S as in Kuhelj et al. (1995),
Kregar et al. (1977), Dolinar et al. (1995), Hwang and Chung
(2002) and Bro¨mme et al., (1993), respectively, and cathepsin X
according to Klemencˇicˇ et al. (2000). Bovine trypsin was
obtained from Sigma-Aldrich.
Cloning and expression of testican Tg-1 domain
The DNA segment coding for the Tg-1 domain of testican (res-
idues Gly310–Glu379) was amplified with the primers 59-GGA TCC
CTC GAG AAA AGA GAG GCT GAA GCT GGT CTC CCT TGC
CAG AAT GAA ATG AAC AGA ATT-39 (sense), and 59-AAT TCG
CGG CCG CTT ACT CCT CTT CAC AGC T-39 (antisense) using
a plasmid encoding full-length testican as a template. The ampli-
fied DNA was digested with XhoI and NotI restriction endonu-
cleases and ligated into pPIC9 digested with the same enzymes.
The recombinant construct was amplified in Escherichia coli
strain DH5a and the correct construction of the plasmid was
confirmed by restriction analysis and DNA sequencing using an
ABI PRISM 310 DNA sequencer (Perkin Elmer, Wellesley, MA,
USA). After linearisation of the pPIC9 construct with SalI, the
Pichia pastoris strain GS115 was transformed by electroporation
with Gene Pulser (Bio-Rad, Hercules, CA, USA) according to the
manufacturer’s protocol. The transformed cells were plated on
MD agar plates w0.34% yeast nitrogen base (YNB), 1% ammo-
nium sulfate, 400 mg/l biotin, 2% D-glucose, 1.5% agarx. Result-
ing colonies were used to inoculate 10 ml of BMGY medium (1%
yeast extract, 2% peptone, 100 mM potassium phosphate,
pH 6.0, 0.34% YNB, 1% ammonium sulfate, 400 mg/l biotin, 1%
glycerol) and grown overnight at 308C in a shaking incubator at
250 rpm. Cells were collected by centrifugation (2500 g for 5 min
at 238C) and gently resuspended in 10 ml of BMMY medium
(same as BMGY medium but containing 0.5% methanol instead
of 1% glycerol). Cultures were incubated for an additional 96 h
with daily supplements of 50 ml of methanol. Clone production
was monitored by electrophoretic analysis of the supernatants
on 12% polyacrylamide SDS gels (Laemmli, 1970). The colony
with the highest expression level of testican Tg-1 domain was
used to prepare protein in larger quantities, using 2-l shake-
flasks under the conditions specified above. The cells were pel-
leted and the supernatant was stored at -208C.
Purification of the Tg-1 domain
Ammonium sulfate was added to culture supernatants to a final
concentration of 1.0 M and the pH was adjusted to 6.0. The
protein solution was loaded onto a phenyl-Sepharose column
equilibrated with 0.1 M phosphate buffer containing 1.0 M
ammonium sulfate. Proteins were eluted with a linear gradient
of ammonium sulfate (from 1 to 0 M) in 0.1 M phosphate buffer,
pH 6.0 and analysed by SDS-PAGE, in which the Tg-1 domain
of testican migrated as a band with a molecular mass of approx-
imately 8 kDa. Fractions containing testican domain were further
purified on a Sephadex G-50 column equilibrated with 0.01 M
Tris/HCl buffer, pH 7.3 in 0.1 M NaCl. Final purification of the
testican domain was achieved by ion-exchange chromatography
on SP Sepharose FF pre-equilibrated with 0.01 M acetate buffer,
pH 4.5. Proteins were eluted with a linear gradient of NaCl
(0–0.5 M) in the same buffer. The concentration of the Tg-1
domain was determined spectrophotometrically using an
absorption coefficient of 9890 M-1 cm-1 at 280 nm.
N-Terminal sequence determination
N-Terminal sequencing was carried out by automated Edman
degradation using an Applied Biosystems liquid pulse sequencer
475A (Foster City, CA, USA) connected on line to a phenylthio-
hydantoin analyser 120A from the same manufacturer.
Circular dichroism spectroscopy
The far-UV CD spectrum of recombinant Tg-1 domain of testican
was measured at 48C on an Aviv 60DS spectrometer (Piscata-
way, NJ, USA) using a quartz cell with 1-mm path length. In the
wavelength region 250–185 nm, data points were recorded at
1-nm intervals with a dwell time of 10 s. Protein was dissolved
at 0.1 mg/ml in 10 mM sodium phosphate buffer, pH 5.6. For
thermal denaturation, the sample was exposed to 888C for 1 h
in the presence of 12.5 mM dithiothreitol (DTT) and the spectra
were recorded at 888C. To confirm the absence of turbidity, the
absorbance of protein solutions was scanned from 350 to
240 nm on a Lambda 18 spectrophotometer (Perkin Elmer) prior
to CD measurement.
Kinetic measurements
Enzymes were assayed following standard procedures using the
substrate Z-Phe-Arg-MCA for papain, cathepsins L and cathep-
sin K, Z-Arg-Arg-MCA for cathepsin B, Z-Phe-Val-Arg-MCA for
cathepsin S, and 2,4-dinitrophenyl-Gly-Phe-Phe-Trp-OH for
cathepsin X. Inhibitory effects of the testican Tg-1 domain were
studied by incubating it with an enzyme for 30 min at 258C
before adding the substrate and measuring the residual activity.
The kinetic inhibition mechanism of cathepsin L by the Tg-1
domain was investigated under pseudo-first-order conditions
essentially as described for the equistatin Tg-1 type inhibitor
(Lenarcˇicˇ et al., 1997). Testican Tg-1 domain (2.9–12 nM final
concentration) and the fluorogenic substrate Z-Phe-Arg-MCA
(10 mM final concentration) were dissolved in 1.97 ml of 0.1 M
sodium acetate buffer, pH 5.50 containing 1 mM EDTA, at 248C.
The reaction was started by the addition of 30 ml of cathepsin
L, which was pre-activated with DTT, giving a final enzyme con-
centration of 22 pM. Progress curves were recorded for
30–60 min on a C-61 fluorimeter (Photon Technology Interna-
tional, Lawrenceville, GA, USA) and the conditions chosen
assured less than 8–10% substrate consumption during each
experiment. Primary data consisted of an exponential rise in
product concentration followed by a linear steady state, a typical
characteristic of slow-binding inhibition (Morrison, 1982). The
general, integrated rate equation wEq. (1)x was fitted to data to
obtain best fits of the parameters ys (velocity at steady state),
yz (velocity at time zero), and l (apparent pseudo-first-order rate
constant for exponential approach to a steady state).
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Figure 3 Amino acid sequence alignment of the p41 fragment and testican Tg-1 domain.
Alignment was carried out with the algorithm of the Modeler program (Sˇali and Blundell, 1993). Identical amino acids are indicated
by shaded boxes. The position of inserted amino acids is underlined. Numbers above the sequences denote the positions of loops.
yltw xPsy tqyyy 1ye yl (1)Ž .Ž .s z s
ys, yz and l were then plotted against the Tg-1 concentration
to determine the inhibition mechanism.
The Selwyn (1965) method, which consists of plotting pro-
gress curves as product concentration vs. enzyme concentration
multiplied by time, was used to check any loss of enzyme activ-
ity by denaturation, adherence to the cuvette walls or other
causes during the relatively long incubation required by the
experiments. There was no enzyme activity loss for measure-
ment times of up to at least 20 min, so that data collected in
this time range were selected for calculations.
Proteolytic cleavage of Tg-1 domain of testican
The proteolytic degradation of testican Tg-1 domain (2.1–3.5mM
final concentration) by activated cathepsin L (0.39 mM final con-
centration) or cathepsin K (40 nM final concentration) was carried
out in 0.1 M sodium acetate buffer, pH 5.50, containing 1 mM
EDTA. The mixtures were incubated for different periods of time
at 258C. The progress of degradation was followed on an
reverse-phase HPLC system (HP 1100, Hewlett-Packard, Palo
Alto, CA, USA) using a CromSpher C18 (Varian, Palo Alto, CA,
USA) column equilibrated with 0.1% (v/v) trifluoroacetic acid in
water. Elution of peptides was carried out with 90% (v/v) ace-
tonitrile containing 0.1% (v/v) trifluoroacetic acid. In control
experiments, testican Tg-1 and cathepsins L and K were sepa-
rately incubated under the same conditions for 60 min at 378C.
Progress curves for Tg-1 domain degradation by cathepsin L
were analysed using the integrated Michaelis-Menten equation
as described by Duggleby (2001).
Identification of cleavage sites by MALDI-TOF
Samples for identification of cleaved bonds were prepared as
described under Proteolytic cleavage of Tg-1 domain of testican.
Mixtures of peptides were desalted on a reverse-phase HPLC
system with a short run (2 min) in an acetonitrile gradient and
analysed by MALDI-TOF. Desalted peptides were dried and dis-
solved in a saturated solution of a-cyano-4-hydroxycinnamic
acid in 0.1% trifluoroacetic acid (v/v), 60% (v/v) acetonitrile and
placed on the MALDI target. MALDI data were recorded on a
Bruker Biflex III (Billerica, MA, USA) instrument equipped with a
scout ion source. Spectra were acquired with pulsed ion extrac-
tion in reflectron mode using a 337-nm nitrogen laser.
Homology modelling
The models of complexes of testican Tg-1 domain with papain
and cathepsins K and L were calculated with the homology
modelling program Modeler (Sˇali and Blundell, 1993) using the
crystal structures of papain (Kamphuis et al., 1984), cathepsin K
(Zhao et al., 1997) and p41 fragment complexed with cathepsin
L (Guncˇar et al., 1999) as templates (PDB codes 9PAP, 1ATK
and 1ICF, respectively). Prior to modelling, the template struc-
tures were cleaned of water molecules and non-native atoms
(oxygen atoms on oxidised Cys25 in papain and E-64 in the
cathepsin K structure). In the initial modelling stage, the align-
ments of the Tg domains (Figure 3) and of the peptidases were
used, along with template structures to build 20 models of each
complex. During this stage the segment of the Tg-1 domain
including residues Cys4–Leu14 was restrained to an a-helical
conformation based on predictions by the PsiPred program
(McGuffin et al., 2000). For each complex, one model was cho-
sen from the pool of the initial 20 and the segment Ser15–Ala23
of the domain was subjected to a long simulated annealing
refinement protocol implemented in Modeler. Of the 20 refined
models, five models with the lowest value of the Modeler objec-
tive function were checked with PROCHECK (Laskowski et al.,
1996) and analysed.
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